Taiwan study reveals HER2 rates in Hard-to-Treat gynecologic cancers

NCT ID NCT06925113

Completed Knowledge-focused Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at medical records from 509 adults in Taiwan to find out how often advanced cervical, endometrial, and ovarian cancers have a specific marker called HER2 IHC 3+. Researchers also described the patients' health details to better understand who might benefit from newer targeted therapies. No treatments were given—this was purely an information-gathering study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma endometrial cancer endometrial carcinoma endometrium neoplasm ovarian cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCERS ENDOMETRIAL CANCER OVARIAN CANCER

Contacts and locations

Locations

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 833, Taiwan
Mackay Memorial Hospital

Taipei, 104, Taiwan
National Taiwan University Hospital

Taipei, 100, Taiwan
Taichung Veterans General Hospital

Taichung, 407, Taiwan
Taipei Veterans General Hospital

Taipei, 112, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.